Design and synthesis of novel pyrazolopyrimidine candidates as promising EGFR-T790M inhibitors and apoptosis inducers.

Our objective was to design and synthesize a new range of pyrazolopyrimidines while maintaining the key pharmacophoric features of EGFR tyrosine kinase inhibitors. Percentage inhibition in 14 human cancer cell lines and IC values were recorded. Compounds , and were examined against both wild and mutant (T790M) EGFR subtypes.